Bermuda-based Conduit Re generated gross premiums written (GPW) of $1.16 billion in 2024, an increase of almost 25% ...
Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River’s immunology expertise to refine study ...
We recently compiled a list of the 11 AI News and Ratings You Shouldn’t Miss. In this article, we are going to take a look at ...
Conduit Pharmaceuticals Inc. (NASDAQ:CDT), a Delaware-based pharmaceutical company with a market capitalization of $2.18 million, has announced the full repayment of a $600,000 promissory note, ...
Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing ...
Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles ...
Conduit Pharmaceuticals (CDT) announces the repayment of its $600,000 promissory note to Nirland and provided an update on the conversion of ...
Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, which will focus on developing personalized ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback